Is Intuitive Surgical a Strategic Buy Ahead of Its July 16 Earnings Report?

Intuitive Surgical (NASDAQ: ISRG) is set to release its earnings report after the market closes on July 16. Despite a robust first-quarter performance, the robotic surgery leader has seen its stock decline by just over 30% so far this year.

While entering a position immediately before an earnings announcement introduces inherent event risk, the current fundamentals for Intuitive Surgical suggest a compelling bullish case.

The company has demonstrated a consistent ability to exceed market expectations, outperforming analyst estimates in each of the last four quarters. Should Intuitive Surgical beat the projected revenue of $2.81 billion and earnings per share (EPS) of $2.48, a positive stock price movement is likely. However, long-term investors should focus on the company’s broader growth potential.

Three primary factors support the long-term investment thesis for Intuitive Surgical:

Attractive Valuation for a Market Leader

Historically, Intuitive Surgical has traded at a premium due to its dominance in the robotic surgery sector. However, this year’s sell-off has compressed its forward price-to-earnings (P/E) multiple to approximately 36x, a significant discount compared to its five-year historical average of over 58x. This provides a potentially attractive entry point into a business where more than 80% of revenue is recurring and highly durable, sourced from instruments, accessories, and services.

In the first quarter, recurring revenue from instruments and services rose 23% year-over-year to $2.12 billion. This growth was fueled by a 16% increase in da Vinci procedure volume and a 39% surge in Ion procedure volume.

Once a hospital integrates these systems, they become deeply embedded in the Intuitive ecosystem, ensuring a reliable and consistent revenue stream.

First-quarter results showed double-digit growth in both revenue ($2.77 billion, up 23% YoY) and EPS ($2.28, up nearly 19% YoY).

Investor concerns regarding GLP-1 obesity drugs and reduced bariatric surgery volumes are being offset by expansion into other medical specialties. Additionally, while the company’s strategy to extend instrument lifespan may impact short-term accessory revenue, it strengthens customer loyalty and deepens its competitive moat.

Story Continues

Momentum from the da Vinci 5 Platform

A major near-term catalyst is the rollout of the next-generation da Vinci 5 system. Preliminary data indicates that hospital utilization of the da Vinci 5 is approximately 11% higher than the legacy Xi platform. Rapid customer adoption and an accelerating upgrade cycle could lead to significant upside surprises in system placements and future guidance.

During the first quarter of 2026, the company placed 232 da Vinci 5 systems, a significant increase from the 147 placed in the same period in 2025.

The da Vinci 5 platform introduces advanced hardware-enabled AI and Force Feedback technology, allowing surgeons to experience physical resistance and tissue pressure. This technological leap establishes a new standard for surgery for the next decade and creates a formidable barrier to entry for competitors.

Expansion into Diagnostics and Soft Tissue Treatment

While Intuitive has traditionally focused on surgical treatment via the da Vinci platform, the Ion platform is moving the company upstream into diagnostics and early intervention.

The Ion endoluminal system is a specialized robotic bronchoscopy platform designed for minimally invasive lung biopsies using an ultrathin, flexible robotic catheter.

Ion bolsters Intuitive’s high-margin recurring revenue model through the sale of single-use needles, vision probes, and specialized 3D planning software. Furthermore, the integration of technologies like endobronchial ultrasound (EBUS) is expected to increase revenue per procedure.

Intuitive is also strengthening its presence in soft tissue treatment via the da Vinci SP (Single Port) platform. This system allows for surgery through a single 2.5-centimeter incision or a natural orifice, and is seeing rapid adoption in urology and head and neck surgeries.

Consequently, Intuitive Surgical appears undervalued heading into its Q2 report, presenting a favorable setup for multi-year investors.

Source link